MXPA05005545A - Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos. - Google Patents

Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.

Info

Publication number
MXPA05005545A
MXPA05005545A MXPA05005545A MXPA05005545A MXPA05005545A MX PA05005545 A MXPA05005545 A MX PA05005545A MX PA05005545 A MXPA05005545 A MX PA05005545A MX PA05005545 A MXPA05005545 A MX PA05005545A MX PA05005545 A MXPA05005545 A MX PA05005545A
Authority
MX
Mexico
Prior art keywords
peptides
compositions
endothelial cells
target tumor
tumor
Prior art date
Application number
MXPA05005545A
Other languages
English (en)
Spanish (es)
Inventor
J Ternansky Robert
Original Assignee
Attenuon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon Llc filed Critical Attenuon Llc
Publication of MXPA05005545A publication Critical patent/MXPA05005545A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MXPA05005545A 2002-11-25 2003-11-25 Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos. MXPA05005545A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42917402P 2002-11-25 2002-11-25
US47553903P 2003-06-02 2003-06-02
PCT/US2003/037895 WO2004063213A2 (en) 2002-11-25 2003-11-25 Peptides which target tumor and endothelial cells, compositions and uses thereof

Publications (1)

Publication Number Publication Date
MXPA05005545A true MXPA05005545A (es) 2005-10-18

Family

ID=32397181

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA05005545A MXPA05005545A (es) 2002-11-25 2003-11-25 Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.
MXPA05005469A MXPA05005469A (es) 2002-11-25 2003-11-25 Peptidos que inhibien angiogenesis, migracion celular, invasion celular y proliferacion celular, composiciones y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA05005469A MXPA05005469A (es) 2002-11-25 2003-11-25 Peptidos que inhibien angiogenesis, migracion celular, invasion celular y proliferacion celular, composiciones y usos de los mismos.

Country Status (14)

Country Link
US (2) US20050020810A1 (https=)
EP (2) EP1569678A4 (https=)
JP (2) JP2006515866A (https=)
KR (2) KR20050096917A (https=)
AU (2) AU2003297609A1 (https=)
BR (2) BR0316523A (https=)
CA (2) CA2507045A1 (https=)
EA (2) EA200500870A1 (https=)
HR (2) HRP20050585A2 (https=)
MX (2) MXPA05005545A (https=)
NO (2) NO20053112L (https=)
NZ (2) NZ540363A (https=)
PL (2) PL377701A1 (https=)
WO (2) WO2004047771A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005545A (es) * 2002-11-25 2005-10-18 Attenuon Llc Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.
EP1766405A1 (en) * 2004-05-21 2007-03-28 MDS Inc. doing Business Through Its MDS Pharma Services Division Method of quantifying the cell-binding properties of a medical device
US20060078535A1 (en) * 2004-10-13 2006-04-13 The Regents Of The University Of Michigan Anticancer compounds and methods
KR20070100832A (ko) * 2005-02-01 2007-10-11 아테뉴온, 엘엘씨 항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물
WO2006084016A1 (en) 2005-02-01 2006-08-10 Attenuon, Llc ACID ADDITION SALTS OF Ac-PHSCN-NH2
AU2006350707A1 (en) * 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
AU2016213759B2 (en) * 2006-11-08 2018-03-29 Chongxi Yu Transdermal delivery systems of peptides and related compounds
PL2427475T3 (pl) 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
KR101228668B1 (ko) 2010-09-17 2013-01-31 가톨릭대학교 산학협력단 혈관신생 억제 활성을 갖는 펩타이드 및 이의 용도
CA2839702C (en) 2011-06-23 2021-04-20 Board Of Regents, The University Of Texas System Identifying peptides at the single molecule level
US11435358B2 (en) 2011-06-23 2022-09-06 Board Of Regents, The University Of Texas System Single molecule peptide sequencing
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
JP6206987B2 (ja) * 2012-05-11 2017-10-04 メディカス バイオサイエンシーズ，エルエルシー 網膜剥離の処置のための生体適合性ヒドロゲル製剤
AU2012381990B2 (en) 2012-06-04 2017-02-23 Nutrien Ag Solutions (Canada) Inc. Formulations containing paraffinic oil and anti-settling agent
ES2664411T3 (es) 2013-03-15 2018-04-19 Suncor Energy Inc. Composiciones herbicidas
JP5970439B2 (ja) * 2013-09-20 2016-08-17 チョンシー ユー ペプチド及び関連化合物の経皮送達システム
CA3208970A1 (en) 2014-09-15 2016-05-06 Board Of Regents, The University Of Texas System Improved single molecule peptide sequencing
CA3110800A1 (en) 2018-07-12 2020-01-16 Board Of Regents, The University Of Texas System Molecular neighborhood detection by oligonucleotides
CA3117476A1 (en) 2018-10-05 2020-04-09 Board Of Regents, The University Of Texas System Solid-phase n-terminal peptide capture and release
WO2020150831A1 (en) 2019-01-25 2020-07-30 Suncor Energy Inc. Photosensitizer compounds, methods of manufacture and application to plants
CN113677204B (zh) 2019-02-15 2024-03-05 桑科能源股份有限公司 原卟啉ix衍生物改善植物健康的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4440788A (en) * 1980-05-13 1984-04-03 Mitsubishi Chemical Industries, Limited Cysteine derivatives
WO1981003330A1 (fr) 1980-05-13 1981-11-26 Mitsubishi Chem Ind Derives de la cysteine et leur production
US4394519A (en) * 1982-01-19 1983-07-19 Research Corporation Amino acid blocking agents
GB8504253D0 (en) * 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5229366A (en) * 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
US5149801A (en) * 1990-11-21 1992-09-22 The Regents Of The University Of California Boronated porphyrin compounds
US5561220A (en) * 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5556609A (en) 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
EP0814860B1 (en) 1995-03-14 1999-11-03 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosating unit
US5970974A (en) * 1995-03-14 1999-10-26 Siemens Aktiengesellschaft Dosating unit for an ultrasonic atomizer device
US5618513A (en) 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
CA2265484C (en) * 1996-09-10 2008-12-02 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
US6025150A (en) * 1996-11-21 2000-02-15 The Regents Of The University Of Michigan Methods and compositions for wound healing
US6331409B1 (en) * 1996-11-21 2001-12-18 The Regents Of The University Of Michigan Methods and compositions for wound healing
US6001965A (en) * 1996-11-21 1999-12-14 The Regents Of The University Of Michigan Anticancer compounds and methods
US6011170A (en) * 1997-01-14 2000-01-04 Kaneka Corporation Process for producing of cysteine derivatives
US5994309A (en) * 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
JP2001516055A (ja) * 1997-09-10 2001-09-25 ザ バーナム インスティチュート 腫瘍中の血管形成血管系にホーミングする分子を同定する方法
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
JP2002525265A (ja) 1998-08-14 2002-08-13 アドミニストレイターズ オブ ザ トゥレーン エジュケーショナル ファウンド 成長ホルモン放出活性を有する化合物
ATE366936T1 (de) 2001-01-18 2007-08-15 Univ Michigan Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
MXPA05005545A (es) * 2002-11-25 2005-10-18 Attenuon Llc Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.

Also Published As

Publication number Publication date
US20050020810A1 (en) 2005-01-27
NZ540889A (en) 2008-09-26
CA2506813A1 (en) 2004-07-29
JP2006514116A (ja) 2006-04-27
HRP20050584A2 (hr) 2006-04-30
MXPA05005469A (es) 2005-09-08
EP1569678A4 (en) 2008-01-02
EA200500870A1 (ru) 2006-04-28
JP2006515866A (ja) 2006-06-08
PL377763A1 (pl) 2006-02-20
PL377701A1 (pl) 2006-02-06
HRP20050585A2 (en) 2006-02-28
WO2004063213A3 (en) 2005-03-03
KR20050096917A (ko) 2005-10-06
NO20053111L (no) 2005-08-24
EA200500871A1 (ru) 2006-04-28
WO2004047771A2 (en) 2004-06-10
WO2004063213A2 (en) 2004-07-29
EP1594521A2 (en) 2005-11-16
NZ540363A (en) 2007-11-30
WO2004047771A3 (en) 2005-09-15
CA2507045A1 (en) 2004-06-10
NO20053112L (no) 2005-08-05
EP1594521A4 (en) 2008-01-09
KR20050097494A (ko) 2005-10-07
US7517855B2 (en) 2009-04-14
NO20053112D0 (no) 2005-06-24
AU2003298726A1 (en) 2004-08-10
BR0316550A (pt) 2005-10-04
NO20053111D0 (no) 2005-06-24
BR0316523A (pt) 2005-10-18
US20040162239A1 (en) 2004-08-19
AU2003297609A1 (en) 2004-06-18
EP1569678A2 (en) 2005-09-07

Similar Documents

Publication Publication Date Title
MXPA05005545A (es) Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.
MXPA03000626A (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
MY139078A (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
DK0950096T3 (da) Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse
WO2005030121A3 (en) Compounds, compositions and methods
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
ATE504649T1 (de) Nell-peptidexpressionssysteme und knochenbildende aktivität des nell-peptids
WO2009136290A1 (en) Functionalized pyrrolidines and use thereof as iap inhibitors
TN2009000194A1 (en) Novel antiproliferation antibodies
DK1292673T3 (da) Trombomodulinanaloger til farmaceutisk anvendelse
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
ATE271871T1 (de) Substanzen zur therapie von erkrankungen, die durch hochproliferierende zellen verursacht werden
CY1111004T1 (el) Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης
AU2003260452A8 (en) Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
CA2634902A1 (en) Anticancer agent comprising a peptide
DE602005024161D1 (de) Peptid mit antitumoraler wirkung
WO2006097748A3 (en) Peptide stabilizer compounds and screening method
WO2006029406A3 (en) Methods for treating bone tumors using bone morphogenic proteins
JP2019506167A5 (https=)
AU2003296543A8 (en) Peptides having a high cysteine content
Barnieh Development of novel tumour-activated peptide prodrugs of ATR/ATM inhibitor, AZD6738
JP2021048838A (ja) ペプチド
DE60334778D1 (de) Gewebsspezifische expression
EA201300313A1 (ru) Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний
MX2008006711A (es) Compuestos y metodos de identificación, sintetización, optimización e individualización de moduladores proteinicos.